Amylyx Pharmaceuticals, Inc.
27.20USD
-1.3700 (-4.80%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on AMLX.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | -1 | 0 |
| Cost of Revenue | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | — | — | 0 | 0 | 0 | 0 | -1 | 0 |
| Operating Income | -46 | -44 | -37 | -36 | -43 | -38 | -41 | -76 |
| Net Income | -43 | -41 | -33 | -34 | -41 | -36 | -38 | -73 |
| EPS (Diluted) | -$0.39 | -$0.37 | -$0.28 | -$0.37 | -$0.46 | -$0.42 | -$0.54 | -$1.07 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)